Voyager Therapeutics (NASDAQ:VYGR) Issues Quarterly Earnings Results

Key Points

• Voyager Therapeutics reported a quarterly loss of $0.40 per share, beating the consensus estimate of a $0.48 loss by $0.08. The company continued to post substantial negative profitability metrics, including a net margin of -319.61%.
• VYGR shares rose slightly to $3.13, but remain near their one-year low of $2.93 and below both their 50-day and 200-day moving averages.
• Analyst sentiment is mixed, though MarketBeat lists a consensus “Moderate Buy” rating and an average price target of $16.50; institutional investors own approximately 48% of the company.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) issued its earnings results on Thursday. The company reported ($0.40) earnings per share for the quarter, topping the consensus estimate of ($0.48) by $0.08, Zacks reports. Voyager Therapeutics had a negative net margin of 319.61% and a negative return on equity of 55.97%.

Voyager Therapeutics Stock Performance

VYGR stock traded up $0.03 on Thursday, reaching $3.13. The company had a trading volume of 421,035 shares, compared to its average volume of 646,793. Voyager Therapeutics has a 1 year low of $2.93 and a 1 year high of $5.55. The company's fifty day moving average is $3.42 and its 200 day moving average is $3.74. The company has a market cap of $189.11 million, a P/E ratio of -1.59 and a beta of 1.31.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the company. HC Wainwright reaffirmed a "buy" rating on shares of Voyager Therapeutics in a report on Monday, July 20th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Voyager Therapeutics in a research note on Monday, July 13th. Finally, Wall Street Zen lowered shares of Voyager Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, May 9th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $16.50.

Hedge Funds Weigh In On Voyager Therapeutics

Several hedge funds have recently bought and sold shares of the stock. Wexford Capital LP purchased a new stake in shares of Voyager Therapeutics in the third quarter valued at $42,000. CIBC Asset Management Inc purchased a new stake in Voyager Therapeutics during the 4th quarter worth about $45,000. Coldstream Capital Management Inc. purchased a new stake in Voyager Therapeutics during the 3rd quarter worth about $55,000. Occudo Quantitative Strategies LP acquired a new position in Voyager Therapeutics in the 2nd quarter valued at about $78,000. Finally, Jane Street Group LLC raised its stake in Voyager Therapeutics by 92.6% in the 2nd quarter. Jane Street Group LLC now owns 27,844 shares of the company's stock valued at $87,000 after purchasing an additional 13,389 shares during the last quarter. Hedge funds and other institutional investors own 48.03% of the company's stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company's core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm's pipeline includes several AAV-based candidates in preclinical and early clinical development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source